Merck Sharp & Dohme LLC — Sponsor Intelligence | 294 EU Trials

Filter these 294 trials by condition, phase, country and more.

Open in Search →

294 Registered trials

89 Recruiting

193 Completed trials

25 Countries active

169 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I (Other)

Phase III: 117 Phase II/III: 15 Phase II: 61 Phase I/II: 33 Phase III/IV: 5 Phase I: 24 Phase I (Other): 36 Phase I (FiH): 3

Oversight events:

4 serious breaches 75 temporary halts 6 urgent safety measures 10 unexpected events 9 corrective measures across 38 trials

View oversight register →

100%

193 of 193 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer metastatic 8 Renal cell carcinoma 8 Non-small cell lung cancer 7 Non-alcoholic steatohepatitis 4 Respiratory syncytial virus infection 4 Non-small cell lung cancer stage IV 3 Pulmonary arterial hypertension 3 Rheumatoid arthritis 3 Bladder cancer 3 Hormone receptor positive HER2 negative breast cancer 3 Prostate cancer metastatic 3 Hormone receptor positive breast cancer 2

Top IMPs

PEMBROLIZUMAB 113 LENVATINIB 26 SACITUZUMAB TIRUMOTECAN 23 PEMBROLIZUMAB, VIBOSTOLIMAB 13 PEMBROLIZUMAB, FAVEZELIMAB 12 BELZUTIFAN 11 OLAPARIB 11 MK-4830 10 MRNA-4157 10 IFINATAMAB DERUXTECAN 8 PATRITUMAB DERUXTECAN 8 PEMBROLIZUMAB, QUAVONLIMAB 8

All trials — page 11

294 total

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal … Ended

2022-501342-29-00 Phase III 6 countries LENVATINIB; PEMBROLIZUMAB
Phase 2 Study of MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular C… Ended

2023-505698-34-00 Phase II 3 countries LENVATINIB; PEMBROLIZUMAB; PEMBROLIZUMAB, QUAVONLIMAB
A Study of the Efficacy and Safety of MK-5475 in Participants with Pulmonary Arterial Hypertension Ended

2022-500877-15-00 Phase II/III 7 countries 3-(4-{(5S)-4-AMINO-2-[6-CHLORO-1-(3,3,4,4,4-PENTAFLUOROBUTYL)-1H-INDAZOL-3-YL]-5…
Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain M… Ended

2023-506315-17-00 Phase I/II 6 countries LENVATINIB; PEMBROLIZUMAB; PEMBROLIZUMAB, QUAVONLIMAB
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) Ended

2022-500821-34-00 Phase I 2 countries
Phase 2 study of Pembrolizumab given every 6 weeks to participants diagnosed with Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL… Ended

2024-510979-38-00 Phase II 3 countries PEMBROLIZUMAB
A study of MK7684A versus Pembrolizumab in PD-L1 Positive Metastatic NSCLC (KEYVIBE-003) Ended

2023-505362-28-00 Phase III 2 countries PEMBROLIZUMAB; PEMBROLIZUMAB, VIBOSTOLIMAB
MK-7684A (new drug co-formulation of pembrolizumab with an anti-TIGIT) plus docetaxel works to help stop or slow down the growth of your non… Ended

2022-501252-28-00 Phase II 9 countries PEMBROLIZUMAB, VIBOSTOLIMAB
Dose Ranging, Switch Study of ISL and MK‑8507 Once-Weekly Ended

2024-511041-19-00 Phase II 1 country ISLATRAVIR; ULONIVIRINE
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Ga… Ended

2023-504834-23-00 Phase III/IV 7 countries CALCIUM FOLINATE; CALCIUM FOLINATE PENTAHYDRATE; LENVATINIB; PEMBROLIZUMAB
Pembrolizumab + Lenvatinib for First Line Non-Clear Cell, Renal Cell Carcinoma Ended

2023-504944-32-00 Phase II 5 countries LENVATINIB; PEMBROLIZUMAB
Substudy to test investigational agents with pembrolizumab in combination with chemotherapy in treatment-naïve NSCLC in a rolling arm design Ended

2023-506932-33-00 Phase II 4 countries BOSEROLIMAB; MK-0482; MK-4830; PEMBROLIZUMAB; VIBOSTOLIMAB
Substudy to test investigational agents in combination with pembrolizumab in PD-L1 positive treatment-naïve NSCLC in a rolling arm design Ended

2023-506933-32-00 Phase II 4 countries MK-0482; MK-4830; PEMBROLIZUMAB
Substudy to test investigational agents in combination with pembrolizumab in patients with PD-(L)1 refractory NSCLC in a rolling-arm design Ended

2023-506934-56-00 Phase II 4 countries BOSEROLIMAB; MK-0482; MK-4830; PEMBROLIZUMAB
Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants with Melanoma (KEYMAK… Ended

2023-506313-21-00 Phase I/II 6 countries LENVATINIB; PEMBROLIZUMAB; PEMBROLIZUMAB, FAVEZELIMAB; PEMBROLIZUMAB, QUAVONLIMA…
Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melano… Ended

2023-506314-51-00 Phase I/II 2 countries GEBASAXTUREV; MK-4830; PEMBROLIZUMAB; PEMBROLIZUMAB, FAVEZELIMAB; VIBOSTOLIMAB
Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refracto… Ended

2023-506312-41-00 Phase I/II 2 countries LENVATINIB; PEMBROLIZUMAB; QUAVONLIMAB; VIBOSTOLIMAB
Clinical Trial of Lenvatinib, Pembrolizumab, and Standard Chemotherapy for Head and Neck Squamous Cell Carcinoma That has Returned or Spread Ended

2022-500820-31-00 Phase II 6 countries LENVATINIB; PEMBROLIZUMAB
A Study of Lenvatinib for Pediatric Patients with Relapsed or Refractory Solid Tumors Ended

2024-512135-80-00 Phase II 4 countries LENVATINIB
Phase 3 Study of Pembrolizumab and Lenvatinib in Combination with TACE for Incurable/Non-metastatic Hepatocellular Carcinoma Ended

2022-502116-36-00 Phase III 9 countries LENVATINIB; PEMBROLIZUMAB
Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide plus ADT in mHSPC Ended

2023-507024-24-00 Phase III 3 countries
Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer Ended

2022-501972-25-00 Phase III 12 countries PEMBROLIZUMAB
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) Ended

2023-509542-35-00 Phase I (Other) 4 countries
Safety and pharmacokinetics of ceftolozane/tazobactam in pediatric participants with nosocomial pneumonia Ended

2022-501110-56-00 Phase I (Other) 3 countries TAZOBACTAM, CEFTOLOZANE

Showing 241–264 of 294 trials

← All sponsors A–Z